gms | German Medical Science

43. Kongress der Deutschen Gesellschaft für Rheumatologie, 29. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie, 25. Wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie

02.-05. September 2015, Bremen

Poster
Posterwalk „Spondyloarthritiden II“

Meeting Abstract (SpA.16)

Long-term (104-Week) Efficacy and Safety of Apremilast Monotherapy in DMARD-Naive Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 4)

Wells AF, Schett G, Edwards C, Adebajo A, Kivitz A, Shah K, Hu C, Aelion JA
[Volltext]
Meeting Abstract (SpA.17)

Sustained and similar clinical response to etanercept after 6 years of treatment in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: long-term results of the ESTHER trial

Poddubnyy D, Song IH, Hermann KG, Haibel H, Callhoff J, Listing J, Buß B, Lange E, Rudwaleit M, Sieper J
[Volltext]
Meeting Abstract (SpA.18)

CERTOLIZUMAB PEGOL verbessert extraartikuläre Manifestationen bei Psoriasis Arthritis: 96-Wochen Daten der RAPID-PsA-Studie

Fitzgerald O, Fleischmann RM, Bengt H, Peterson L, Gladman D
[Volltext]
Meeting Abstract (SpA.19)

Apremilast, an Oral Phophodiesterase 4 Inhibitor, Is Associated With Long-term (52-Week) Improvements in Enthesitis and Dactylitis in Patients With Psoriatic Arthritis: Results From the PALACE 4 Phase 3, Randomized, Controlled Trial

Edwards C, Wollenhaupt J, Adebajo A, Kivitz A, Bird P, Hu C, Aelion JA, Wells AF
[Volltext]
Meeting Abstract (SpA.20)

Secukinumab Inhibits Radiographic Progression in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (FUTURE 1)

Rech J, van der Heijde D, Landewé R, Mease P, McInnes I, Conaghan P, Pricop L, Ligozio G, Richards HB, Mpofu S
[Volltext]
Meeting Abstract (SpA.21)

A Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-term (52-Week) Improvements in Physical Function

Wells AF, Schett G, Adebajo A, Kivitz A, Hu C, Edwards C, Bird P, Aelion JA
[Volltext]
Meeting Abstract (SpA.22)

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-term (52-Week) Improvement in Measures of Disease Activity in Patients With Psoriatic Arthrithis: Results From 3 Phase 3, Randomized, Controlled Trials

Kavanaugh A, Wollenhaupt J, Cutolo M, Mease P, Gladman D, Adebajo A, Gomez-Reino JJ, Schett G, Lespessailles E, Hu C, Edwards C, Birbara CA
[Volltext]
Meeting Abstract (SpA.23)

Functional status remains stable despite continuous radiographic spinal progression over ten years under anti-TNF therapy in patients with ankylosing spondylitis

Poddubnyy D, Fedorova A, Listing J, Dyck H, Haibel H, Baraliakos X, Braun J, Sieper J
[Volltext]
Meeting Abstract (SpA.24)

Fluoreszenz-optische Bildgebung als Biomarker zur Detektion subklinischer entzündlicher Aktivität des Bewegungsapparates in Patienten mit Psoriasis Vulgaris – erste Interims Analyse des XCITING Projekts

Köhm M, Rossmanith T, Langer HE, Backhaus M, Käßer UR, Kneitz C, Wassenberg S, Amberger C, Burkhardt HL, Behrens F
[Volltext]
Meeting Abstract (SpA.25)

No differences in the rate of new fatty lesions following resolution of inflammation on MRI between infliximab added to naproxen and naproxen alone in early axial spondyloarthritis: results from the Part I of the INFAST study

Poddubnyy D, Sieper J
[Volltext]
Meeting Abstract (SpA.26)

Assessment of spinal mobility in axial spondyloarthritis – first validation steps of a new electronic quantification tool

Kiefer D, Baraliakos X, Herbold S, Braun J
[Volltext]
Meeting Abstract (SpA.27)

Klinisches Ansprechen der axialen Spondyloarthritis auf CERTOLIZUMAB PEGOL geht mit gesteigerter Produktivität sowohl am Arbeitsplatz als auch im Haushalt einher

van der Heijde D, Braun J, Rudwaleit M, Purcaru O, Kavanaugh A
[Volltext]
Meeting Abstract (SpA.28)

Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)

Kavanaugh A, Schett G, Adebajo A, Gladman D, Gomez-Reino JJ, Hall S, Lespessailles E, Mease P, Shah K, Hu C, Wollenhaupt J
[Volltext]